CTA
SAGE

Carillon Tower Advisers’s Sage Therapeutics SAGE Stock Holding History

Carillon Tower Advisers’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-400,648
Closed -$56.2M – 484
2019
Q3 		$56.2M Hold
400,648
– – 0.39% 78
2019
Q2 		$73.4M Hold
400,648
– – 0.5% 52
2019
Q1 		$63.7M Sell
400,648
-89,174
-18% -$12.9M 0.45% 57
2018
Q4 		$46.9M Buy
489,822
+21
+0% +$2.4K 0.4% 72
2018
Q3 		$69.8M Buy
489,801
+58,078
+13% +$8.96M 0.5% 50
2018
Q2 		$67.6M Sell
431,723
-19,374
-4% -$3.04M 0.53% 45
2018
Q1 		$65.8M Hold
451,097
– – 0.51% 43
2017
Q4 		$74.3K Buy
+451,097
New +$43.7M 0.79% 20

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Carillon Tower Advisers's SAGE Position: Q4 2019 in Review

Carillon Tower Advisers sold out of Sage Therapeutics (SAGE) in Q4 2019, closing a stake of 400,648 shares — an estimated $56.2M sold.

Carillon Tower Advisers first reported a position in SAGE in Q4 2017 and held it in 8 quarters. The position peaked at $73.4M in Q2 2019. 266 funds tracked by Wall St. Rank hold SAGE as of Q4 2019.

  • Carillon Tower Advisers reported no remaining Sage Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Carillon Tower Advisers sold 400,648 Sage Therapeutics shares in Q4 2019, an estimated $56.2M.
  • Carillon Tower Advisers first reported a position in Sage Therapeutics in Q4 2017 and held it in 8 quarters.
  • Carillon Tower Advisers's Sage Therapeutics position peaked at $73.4M in Q2 2019.
  • 266 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2019.

Based on Carillon Tower Advisers's 13F filing for Q4 2019, filed 11 Feb 2020.